Chiome Bioscience Inc.
Notice Regarding Patent Allowance in the United States for Humanized DLK-1 Antibody in Combination with Lenvatinib
Received notice of patent allowance in the United States for the combination of the humanized DLK-1 antibody (CBA-1205) and lenvatinib. CBA-1205 is a humanized monoclonal antibody targeting solid tumors such as hepatocellular carcinoma, currently in a domestic Phase 1 trial. While the patent allowance strengthens the intellectual property foundation, its impact on the 2026 fiscal year results is unknown or not disclosed.
Key Figures
- Patent Application US No. 17/599,820
- Notice of patent allowance
- Phase 1 clinical trial of CBA-1205 domestically
AI要約
Section Heading
This disclosure provides information regarding the notice of allowance for a United States patent related to humanized DLK-1 antibody and its use in combination with lenvatinib. The patent covers antibodies targeting human DLK-1, including CBA-1205, and combination therapy with lenvatinib; patents have already been granted in Japan, China, and Europe. The U.S. allowance is described as strengthening the company’s intellectual property foundation supporting development and exploitation activities, and is stated to have no direct impact on the 2026 fiscal year performance. The plan remains to obtain safety and efficacy data from Phase 1 trials and pursue licensing to a pharmaceutical company.
Section 2 Heading
DLK-1 is described as a factor that regulates proliferation and differentiation of immature cells, with potential as a target in hepatocellular carcinoma. With patent grants in Japan, China, and Europe, receiving U.S. patent allowance is a key element supporting the company's IP strategy and clinical development progress. However, the direct financial impact is considered limited, and longer-term value may depend on future clinical data and licensing outcomes.
Chiome Bioscience Inc.
Company overview · Stock price · Financial data · All IR
